<DOC>
	<DOCNO>NCT00567346</DOCNO>
	<brief_summary>The study assess efficacy safety three different dosage regimen grass pollen sublingual immunotherapy adult patient suffer grass pollen relate rhinoconjunctivitis .</brief_summary>
	<brief_title>Efficacy Safety Grass Pollen Sublingual Immunotherapy</brief_title>
	<detailed_description>Patients seasonal grass pollen relate rhinoconjunctivitis randomize one four treatment group 41 centre Europe . Each treatment group consist approximately 150 patient 150 patient randomized placebo group . The study consist screen phase , treatment phase variable maintenance period .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>male female aged 1850 patient grass pollen related allergic rhinoconjunctivitis least 2 pollen season Positive skin prick test IgE value least Class 2+ RTSS great equal 14 pollen season prior tot start study Patients must general good health Patients normal spirometry Informed consent give willing comply protocol Female patient eligible use accept contraceptive method Negative urine pregnancy test female Pregnancy , breast feeding Asthma require treatment beta2 inhaled agonist patient take oral steroid within 12 week screen visit patient receive desensitisation treatment grass pollen treatment immunotherapy allergen within previous 5 year patient suffer low respiratory tract infection within 4 week upper respiratory tract infection within 2 week screen visit patient risk noncompliance participation clinical study within previous 3 month patient past current disease , may affect participation outcome study . patient treat betablockers continuous corticotherapy allergic sensitivity epithelial allergens patient expose positive skin prick test environmental allergen suffer serious allergic symptom due exposure allergen study period intention subject patient surgery nasal cavity current study Usual contraindication immunotherapy clinical history symptomatic seasonal allergic rhinitis and/or asthma due tree pollen weed pollen adjacent start , potentially overlap grass pollen season</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>randomise</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>efficacy safety</keyword>
	<keyword>OralgenÂ® Grass Pollen</keyword>
	<keyword>allergic rhinoconjunctivitis</keyword>
	<keyword>Allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Grass pollen extract</keyword>
</DOC>